AU2001278117A1 - Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen - Google Patents

Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Info

Publication number
AU2001278117A1
AU2001278117A1 AU2001278117A AU7811701A AU2001278117A1 AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1 AU 2001278117 A AU2001278117 A AU 2001278117A AU 7811701 A AU7811701 A AU 7811701A AU 2001278117 A1 AU2001278117 A1 AU 2001278117A1
Authority
AU
Australia
Prior art keywords
antigen
endoplasmic reticulum
chaperone polypeptide
reticulum chaperone
molecular vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278117A
Other languages
English (en)
Inventor
Chien-Fu Hung
Tzyy-Choou Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001278117A1 publication Critical patent/AU2001278117A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2001278117A 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen Abandoned AU2001278117A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22290200P 2000-08-03 2000-08-03
US60/222,902 2000-08-03
PCT/US2001/024134 WO2002012281A2 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Publications (1)

Publication Number Publication Date
AU2001278117A1 true AU2001278117A1 (en) 2002-02-18

Family

ID=22834209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278117A Abandoned AU2001278117A1 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Country Status (8)

Country Link
US (3) US7342002B2 (https=)
EP (1) EP1363938B1 (https=)
JP (2) JP5087201B2 (https=)
AU (1) AU2001278117A1 (https=)
CA (1) CA2417214C (https=)
DK (1) DK1363938T3 (https=)
ES (1) ES2454640T3 (https=)
WO (1) WO2002012281A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU2001290520A1 (en) * 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2004092221A1 (ja) * 2003-04-18 2004-10-28 Sekisui Chemical Co. Ltd. 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2005081716A2 (en) * 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
AU2005292852B2 (en) 2004-10-15 2011-02-03 Joe Chiba Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
JP2009526780A (ja) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Ｈｐｖ抗原、ワクチン組成物、および関連する方法
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
WO2008046251A1 (fr) 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008119024A1 (en) * 2007-03-27 2008-10-02 University Of Florida Research Foundation Inc. Modified antigen presenting cells and methods of use
EP2178558B1 (en) * 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
JP2011518115A (ja) * 2008-01-28 2011-06-23 タップイミューン インコーポレイテッド 免疫応答を増強するためのタパシン増加
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CA2736498C (en) * 2008-09-11 2017-05-23 Calretex, Llc Compositions and methods for purifying calreticulin
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
PL2591114T3 (pl) * 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
EP2678031A4 (en) * 2011-02-23 2015-09-02 Univ Miami COMBINED VACCINATION WITH CELL-BASED GP96-IG-SIV / HIV AND THE RECOMBINANT PROTEIN GP120 FOR PROTECTION AGAINST SIV / HIV
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
JP5981921B2 (ja) * 2011-09-02 2016-08-31 株式会社カネカ 小胞体シャペロンプロモータを用いた外来遺伝子を発現するトランスジェニック鳥類
WO2013093629A2 (en) * 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
US9993534B2 (en) * 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017155981A1 (en) * 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
CN109182339A (zh) * 2018-09-06 2019-01-11 青岛农业大学 一种许氏平鮋钙网蛋白基因及应用
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US5582831A (en) * 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1989012455A1 (en) 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
CN1067382A (zh) 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
ES2193133T3 (es) * 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL106760A (en) 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) * 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
EP0659438A1 (en) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5854202A (en) 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
AU5512096A (en) 1995-05-17 1996-11-29 University Of Alberta Method of inhibiting restenosis using calreticulin
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
AU6504596A (en) 1995-07-21 1997-02-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
DE19534348C2 (de) 1995-09-15 1997-07-10 Wieland Heinrich Prof Dr Med Verfahren zur Bestimmung von Autoimmunphänomenen
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
US5951976A (en) * 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
IN183280B (https=) * 1996-09-20 1999-10-30 Univ New Mexico
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CA2287198A1 (en) 1997-04-23 1998-10-29 Shriners Hospital For Children Calreticulin-deficient cells
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
KR20060111731A (ko) 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
CA2685270C (en) 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same
WO1999065940A1 (en) 1998-06-17 1999-12-23 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
EP1728865A1 (en) * 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
DE60038622D1 (de) 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20010034042A1 (en) * 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
AU2001290520A1 (en) 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
JP3930243B2 (ja) * 2000-11-06 2007-06-13 本田技研工業株式会社 マグネットポンプ
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
AU2002242016A1 (en) * 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
AU2002306736A1 (en) 2001-03-16 2002-10-03 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
US20030144221A1 (en) 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
EP1539189A4 (en) 2002-03-25 2007-05-09 Univ Boston METHOD OF USE OF ANTI-APOPTOSIS FACTORS IN GENE EXPRESSION
MXPA05003395A (es) 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
WO2005047501A1 (en) 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005081716A2 (en) 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin

Also Published As

Publication number Publication date
JP5087201B2 (ja) 2012-12-05
JP2004527213A (ja) 2004-09-09
US20130203961A1 (en) 2013-08-08
US20090148471A1 (en) 2009-06-11
EP1363938B1 (en) 2013-12-11
US7342002B2 (en) 2008-03-11
WO2002012281A2 (en) 2002-02-14
JP2009017883A (ja) 2009-01-29
ES2454640T3 (es) 2014-04-11
US20050054820A1 (en) 2005-03-10
US8007781B2 (en) 2011-08-30
CA2417214A1 (en) 2002-02-14
WO2002012281A9 (en) 2003-03-06
EP1363938A2 (en) 2003-11-26
DK1363938T3 (en) 2014-03-24
WO2002012281A3 (en) 2003-07-10
CA2417214C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
AU2001278117A1 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
AU2001290520A1 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
AU2001252458A1 (en) Molecular antigen arrays and vaccines
AU7912100A (en) Pharmaceutical composition comprising an antigen
AU1951201A (en) Peptide antigens
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2002351624A1 (en) Tripartite molecular beacons
AU2003230795A8 (en) Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU2002365924A1 (en) Herbal immune system stimulant
AU2001250212A1 (en) Rhamm peptide conjugates
AU2002219485A1 (en) An autologous anti-cancer vaccine
AU2001242190A1 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
AU2002232803A1 (en) Expression system for recombinant proteins
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU2003228863A1 (en) Immunogenic peptides
AU4990999A (en) Survivin, and peptides thereof, as an anti-cancer vaccine
AU2000277350A1 (en) Labeled peptides, and processes and intermediates useful for their preparation
AU2001227375A1 (en) N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
AU2001241187A1 (en) Sustained release oral preparations
AU2002222139A1 (en) Hcv vaccines
AU2002334631A1 (en) Immune response associated proteins
AU2002311615A1 (en) Compact linear scanner system
AU6224301A (en) Novel plakoglobin interacting proteins
AU2002340092A1 (en) Immunodominant acetylcholine receptor alpha subunit peptide: mhc complexes
AU2001278975A1 (en) Alpha-conotoxin peptides